Press Resease

Metastatic Bone Disease Market - Global Industry Analysis

Metastatic Bone Disease Market by Treatment (Medication, Radiation Therapy, Surgical Intervention, and Tumor Ablation Therapy), by Origin (Breast, Lung, Thyroid, Kidney, Prostate & Others), and by End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017- 2024

Published Date: 23-Jul-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3243 Status : Published

Global metastatic bone disease market expected to generate revenue of around USD 20,992.7 million by end of 2024, growing at a CAGR of around 7.89% between 2018 and 2024. Metastatic bone disease is a condition that arises from cancer spread to the bones at an advanced stage. This condition causes bone degeneration, fractures, severe pain, anemia, and others.

Description

The report covers forecast and analysis for the metastatic bone disease market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the metastatic bone disease market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the metastatic bone disease market on a global level.

In order to give the users of this report a comprehensive view of the metastatic bone disease market, we have included competitive landscape and analysis of Porter’s Five Forces model in the market. The study encompasses a market attractiveness analysis, wherein treatment, origin, end use, and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.

Global Metastatic Bone Disease Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments in the market, including acquisitions & mergers, new treatment launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved on the market on the global and regional basis. 

The study provides a decisive view on the metastatic bone disease market by segmenting the market based on test type, drug type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market are estimated from 2018 to 2024. 

Based on treatment, the metastatic bone disease market is segmented as medication, radiation therapy, surgical intervention, and tumor ablation therapy. Based on origin, the metastatic bone disease market is segmented as breast, lung, thyroid, kidney, prostate, and others. Based on the end user, the metastatic bone disease market is segmented as hospitals, specialty clinics, and ambulatory surgical centers

Increased prevalence of cancer is one of the major driving factors of metastatic bone disease market. High investment on the drug discovery and development which is further supported the FDA approval of various drugs for the treatment of metastatic bone disease market. A long interval of time is required for the developments of drugs are the factors that influence the market growth during the forecast period.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries, including the U.S., Germany, France, UK, China, Japan, India, and Brazil. This segment includes the demand for metastatic bone disease market based on individual segment and treatment in all the regions and countries.

The report also includes detailed profiles of end players such as Merck & Co., Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Amgen, Inc., Novartis AG, Bayer AG, BTG plc, Fresenius Kabi AG, Medtronic, Boston Scientific Corporation, and others. 

This report segments the global Metastatic Bone Disease Market as follows:

Global Metastatic Bone Disease Market: Treatment Analysis

  • Medication
  • Radiation Therapy
  • Surgical Intervention
  • Tumor Ablation Therapy

Global Metastatic Bone Disease Market: Origin Analysis

  • Breast
  • Lung
  • Thyroid
  • Kidney
  • Prostate 
  • Others

Global Metastatic Bone Disease Market: End User Analysis

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

Global Metastatic Bone Disease Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Metastatic Bone Disease Market, 2015 - 2024 (USD Billion)
    • 2.2. Global Metastatic Bone Disease Market: Snapshot
  •  
  • Chapter 3. Metastatic Bone Disease Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Metastatic Bone Disease Market drivers: Impact analysis
      • 3.2.2. Increased prevalence of cancer
    • 3.3. Market Restraints
      • 3.3.1. Long time required for drug development
      • 3.3.2. High cost of treatment
    • 3.4. Opportunities
      • 3.4.1. Patent Expiry
      • 3.4.2. Use of personalized medicine
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Treatment Type
      • 3.6.2. Market attractiveness analysis, by Origin
      • 3.6.3. Market attractiveness analysis, by End User
      • 3.6.4. Market attractiveness analysis, by Regional Segment
  •  
  • Chapter 4. Global Metastatic Bone Disease Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Metastatic Bone Disease Market: company market share, 2015
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Treatment Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global Metastatic Bone Disease Market - Treatment Segment Analysis
    • 5.1. Global Metastatic Bone Disease Market: Treatment overview
      • 5.1.1. Global Metastatic Bone Disease Market revenue share, by Treatment, 2015 and 2024(USD Billion)
    • 5.2. Medication
      • 5.2.1. Global Medication market, 2015 - 2024(USD Billion)
    • 5.3. Radiation Therapy
      • 5.3.1. Global Radiation Therapy market, 2015 - 2024(USD Billion)
    • 5.4. Surgical Intervention
      • 5.4.1. Global Surgical Intervention market, 2015 - 2024(USD Billion)
    • 5.5. Tumor Ablation Therapy
      • 5.5.1. Global Tumor Ablation Therapy market, 2015 - 2024(USD Billion)
  •  
  • Chapter 6. Global Metastatic Bone Disease Market - Origin Segment Analysis
    • 6.1. Global Metastatic Bone Disease Market: Origin overview
      • 6.1.1. Global Metastatic Bone Disease Market revenue share, by Origin, 2015 and 2024(USD Billion)
    • 6.2. Breast
      • 6.2.1. Global Breast market, 2015 - 2024(USD Billion)
    • 6.3. Lung
      • 6.3.1. Global Lung market, 2015 - 2024(USD Billion)
    • 6.4. Thyroid
      • 6.4.1. Global Thyroid market, 2015 - 2024(USD Billion)
    • 6.5. Kidney
      • 6.5.1. Global Kidney market, 2015 - 2024(USD Billion)
    • 6.6. Prostate
      • 6.6.1. Global Prostate market, 2015 - 2024(USD Billion)
    • 6.7. Others
      • 6.7.1. Global Others market, 2015 - 2024(USD Billion)
  •  
  • Chapter 7. Global Metastatic Bone Disease Market - End User Segment Analysis
    • 7.1. Global Metastatic Bone Disease Market: End User overview
      • 7.1.1. Global Metastatic Bone Disease Market revenue share, by End User , 2014 and 2024(USD Billion)
    • 7.2. Hospitals
      • 7.2.1. Global Metastatic Bone Disease Market for Hospitals, 2015 - 2024(USD Billion)
    • 7.3. Specialty Clinics
      • 7.3.1. Global Metastatic Bone Disease Market for Specialty Clinics, 2015 - 2024(USD Billion)
    • 7.4. Ambulatory Surgical Centers
      • 7.4.1. Global Metastatic Bone Disease Market for Ambulatory Surgical Centers, 2015 - 2024(USD Billion)
  •  
  • Chapter 8. Global Metastatic Bone Disease Market - Regional Segment Analysis
    • 8.1. Global Metastatic Bone Disease Market: Regional overview
      • 8.1.1. Global Metastatic Bone Disease Market revenue share, by Region, 2015 and 2024
    • 8.2. North America
      • 8.2.1. North America Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 8.2.2. North America Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
      • 8.2.3. North America Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
      • 8.2.4. North America Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.2.5. U.S.
        • 8.2.5.1. U.S. Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.2.5.2. U.S. Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.2.5.3. U.S. Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.2.5.4. U.S. Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.2.6.2. Rest of North America Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.2.6.3. Rest of North America Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.2.6.4. Rest of North America Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 8.3.2. Europe Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
      • 8.3.3. Europe Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
      • 8.3.4. Europe Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.3.5.2. Germany Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.3.5.3. Germany Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.3.5.4. Germany Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.3.6. U.K.
        • 8.3.6.1. U.K. Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.3.6.2. U.K. Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.3.6.3. U.K. Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.3.6.4. U.K. Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.3.7. France
        • 8.3.7.1. France Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.3.7.2. France Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.3.7.3. France Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.3.7.4. France Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.3.8.2. Rest of Europe Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.3.8.3. Rest of Europe Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.3.8.4. Rest of Europe Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 8.4.2. Asia Pacific Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
      • 8.4.3. Asia Pacific Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
      • 8.4.4. Asia Pacific Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.4.5. China
        • 8.4.5.1. China Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.4.5.2. China Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.4.5.3. China Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.4.5.4. China Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.4.6. Japan
        • 8.4.6.1. Japan Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.4.6.2. Japan Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.4.6.3. Japan Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.4.6.4. Japan Metastatic Bone Disease Market revenue, by region, 2015 - 2024(USD Billion)
      • 8.4.7. India
        • 8.4.7.1. India Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.4.7.2. India Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.4.7.3. India Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.4.7.4. India Metastatic Bone Disease Market revenue, by region, 2015 - 2024(USD Billion)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.4.8.2. Rest of Asia Pacific Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.4.8.3. Rest of Asia Pacific Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.4.8.4. Rest of Asia Pacific Metastatic Bone Disease Market revenue, by region, 2015 - 2024(USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 8.5.2. Latin America Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
      • 8.5.3. Latin America Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
      • 8.5.4. Latin America Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.5.5.2. Brazil Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.5.5.3. Brazil Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.5.5.4. Brazil Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
        • 8.5.6.2. Rest of Latin America Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
        • 8.5.6.3. Rest of Latin America Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
        • 8.5.6.4. Rest of Latin America Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
    • 8.6. Middle East and Africa
      • 8.6.1. Middle East and Africa Metastatic Bone Disease Market revenue, by Treatment, 2015 - 2024(USD Billion)
      • 8.6.2. Middle East and Africa Metastatic Bone Disease Market revenue, by Origin, 2015 - 2024(USD Billion)
      • 8.6.3. Middle East and Africa Metastatic Bone Disease Market revenue, by End User , 2015 - 2024(USD Billion)
      • 8.6.4. Middle East and Africa Metastatic Bone Disease Market revenue, by Region, 2015 - 2024(USD Billion)
  •  
  • Chapter 9. Company Profile
    • 9.1. Merck & Co. Inc.
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Therapy portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Eli Lilly and Company
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Therapy portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. F. Hoffmann-La Roche Ltd.
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Therapy portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Amgen, Inc.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Therapy portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Novartis AG
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Therapy portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Bayer AG
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Therapy portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. BTG plc
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Therapy portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Fresenius Kabi AG
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Therapy portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Medtronic
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Therapy portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Boston Scientific Corporation
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Therapy portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments

Methodology

Free Analysis

As there are various developments being made in the research field there is also a constant increase in the number of various diseases such as cancer, autoimmune diseases, and others. Bone metastasis is an advanced stage of cancer which spread to other parts of the body which mainly includes lung, liver, and bones. This will add up the treatment cost and the chances of getting cured also reduce. Bone metastasis leads to the degeneration of bones and can cause various fractures which cannot be treated. This can cause severe pain, anemia, spinal cord compression, hypercalcemia, and various other conditions. This can be diagnosed by CT scan and treatment includes prevention and treatment of fractures, pain control, local tumor control, and maintenance of patient function. Treatment options are chosen on various factors which include performance status, impact on quality of life, life expectancy, and the overall status of the clinical disease.

There is a constant increase in the prevalence of cancer over the period of time and reimbursement policies are the major factors driving the growth of metastatic bone disease market over the forecast period. Cancer begins in an organ and then spreads to bones and as per the National Cancer Institute in 2018 an estimated 1,735,350 new cases of cancer will be diagnosed in the United States. The companies are also focused towards developing new and effective treatments for the cancer patients which will further help in providing a better life. 

Global Metastatic Bone Disease Market

The companies are constantly investing in research and development and there are various new drugs being developed by the companies and few are under development. This may further fuel the metastatic bone disease market over the forecast period. Moreover, there are various drugs approved by FDA for treatment and various organizations are creating awareness among people will also support the growth of metastatic bone disease market. However, the high cost of research and development and long duration of product development may hamper the growth of the metastatic bone disease. 

Based on treatment type, the metastatic bone disease market is segmented into medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication segment is expected to grow significantly due to the primary preference for the medication for treatment. Based on origin, the metastatic bone disease market is segmented into breast, lung, thyroid, kidney, prostate, and others. Breast cancer segment is expected to dominate the metastatic bone disease market. Based on the end user, the metastatic bone disease market is segmented into hospitals, ambulatory surgical centers, and specialty clinics. Hospital segment is expected to dominate the metastatic bone disease market over the forecast period.

In terms of region, the global metastatic bone disease market is classified into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. North America is expected to be the largest market for metastatic bone disease market which is further followed by Europe during the forecast period. This growth is supported by an increase in healthcare facilities and an increase in research and development which is further supported by FDA approval of the various new drugs launched in the market. The Asia Pacific is expected to experience a significant growth due to the increased prevalence and awareness among people. Latin America and the Middle East and Africa are expected to experience a moderate growth over the forecast period.

Some of the key players in metastatic bone disease market include Merck & Co., Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Amgen, Inc., Novartis AG, Bayer AG, BTG Plc, Fresenius Kabi AG, Medtronic, Boston Scientific Corporation, and others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social